Population
Human platelets and purified glycoprotein (GP) IIb/IIIa receptor (in vitro model)
Design
Preclinical
Authors
Loading...
Supports further development of nonpeptide GPIIb/IIIa inhibitors; leaves open translation to clinical antithrombotic use.
Novel thiazole-based heterocycles, particularly compound 32, demonstrate potential as nonpeptide inhibitors of fibrinogen-mediated platelet aggregation by blocking GPIIb/IIIa receptor activation.
Sanfilippo et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: